About Genoplan
Genoplan is a company based in New York (United States) founded in 2014. Genoplan has raised $17.25 million across 4 funding rounds from investors including GC Genome, GC Holdings and PIA Investment Management. Genoplan operates in a competitive market with competitors including 23andMe, Color, Veritas Genetics, InformedDNA and Arivale, among others.
- Headquarter New York, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$17.25 M (USD)
in 4 rounds
-
Latest Funding Round
$13 M (USD), Series B
Sep 02, 2018
-
Investors
GC Genome
& 7 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of Genoplan
Unlock access to complete
Unlock access to complete
Unlock access to complete
Funding Insights of Genoplan
Genoplan has successfully raised a total of $17.25M across 4 strategic funding rounds. The most recent funding activity was a Series B round of $13 million completed in September 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Genoplan
Genoplan has secured backing from 8 investors, including institutional and venture fund investors. Prominent investors backing the company include GC Genome, GC Holdings and PIA Investment Management.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked | |
|
Dayli Partners is focused on bio-healthcare and fintech investments.
|
Locked | Locked | Locked | |
|
Investments are directed toward semiconductors, telecommunications, software, and medical sectors.
|
Locked | Locked | Locked |
Investor details for Genoplan
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Genoplan
Investment portfolio details for Genoplan
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Genoplan
Detailed financials for Genoplan
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Genoplan Comparisons
Peer comparison for Genoplan
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Genoplan
Genoplan operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as 23andMe, Color, Veritas Genetics, InformedDNA and Arivale, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Provider of genetic test solutions to study ancestry, genealogy, and inherited traits
|
|
| Locked | Locked | Locked |
Cancer care is delivered through a virtual clinic by Color.
|
|
| Locked | Locked | Locked |
Genetic testing products for health risks and traits are offered.
|
|
| Locked | Locked | Locked |
Network of genetics experts provided to assist patients and providers.
|
|
| Locked | Locked | Locked |
Provider of direct-to-consumer genetic testing.
|
|
| Locked | Locked | Locked |
Provider of a platform for gene analysis to determine genetic diseases and drug response
|
Detailed competitors of Genoplan
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Genoplan
Complete news archive for Genoplan
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Genoplan
Genoplan was founded in 2014 and raised its 1st funding round 1 year after it was founded.
Genoplan is headquartered in New York, United States. It is registered at New York, New York, United States.
Genoplan is a funded company, having raised a total of $17.25M across 4 funding rounds to date.
Genoplan was founded in 2014 and is based in New York, United States. Operations focus on the genetic testing sector, where saliva samples are collected and analyzed for DNA-based health insights. Tailored lifestyle recommendations are generated, covering areas such as diet, health foods, workouts, and cosmetics, to support individual wellness decisions.
Genoplan's top competitors include 23andMe, Veritas Genetics and Color.
Genoplan has 8 investors. Key investors include GC Genome, GC Holdings, PIA Investment Management, Dayli Partners, and Wonik.